Close to one-third of drugs approved by the FDA are found to have safety problems, according to a research report from The Journal of the American Medical Association. JAMA’s report stated that these safety issues, known as “postmarket safety events,” are “common after FDA approval, highlighting the importance of continuous monitoring of the safety of novel therapeutics throughout their life cycle.”